Here is a question nobody asks at the vendor booth: what actually happens after the contract is signed? Everyone in life sciences technology has sat through a keynote about the “integrated commercial ecosystem.” Fewer people have sat down with the person who has to log into four different systems before lunch just to find out whether a key opinion leader has been contacted this quarter. This piece is for the second group.
I spoke with people who actually run these systems day to day — not the ones who buy them, the ones who live in them. What follows is less a market map and more a confession booth: which platforms are really in place, what quietly works, what nobody wants to admit is broken, and where AI is genuine leverage versus expensive theatre.
1. The platforms on the ground, not on the org chart
Ask five APAC commercial leads what their “tech stack” is, and you will not get five clean answers — you will get five archaeology reports. Layer on layer of what regional headquarters mandated, what individual country teams bought around it, and what one enthusiastic brand manager in Seoul is running in a spreadsheet because it is faster than the CRM.
On sales, Veeva CRM remains the dominant system across most large pharma affiliates in Singapore, Japan, South Korea, and Australia, largely because global HQ mandated it years ago. Salesforce Life Sciences Cloud shows up more in medtech and in mid-sized biopharma that never fully committed to Veeva’s ecosystem. IQVIA OCE appears in pockets, often inherited through an acquisition rather than chosen deliberately.
On marketing, the picture is messier. Veeva PromoMats handles approved content in the regulated markets, but the actual campaign and email tooling is a patchwork — Adobe Experience Cloud in some multinationals, Salesforce Marketing Cloud in others, and in more than one APAC affiliate, a local agency’s own platform that nobody at HQ has fully mapped.
Supply chain in the region still runs heavily on SAP, with SAP Business Network and, for a smaller number of players facing serialisation mandates in markets like South Korea and Indonesia, TraceLink or Systech bolted on for track-and-trace compliance.
Medical affairs is where global standardisation is weakest in APAC. Veeva Vault Medical is common among the largest multinationals, but many mid-sized biopharma and medtech affiliates in the region still manage medical information requests through shared inboxes and manually maintained trackers.
Data and analytics is the newest battleground. Snowflake and Databricks adoption is climbing quickly among regional data teams that want to escape vendor lock-in, while IQVIA’s own analytics products remain entrenched wherever market-share reporting is the primary use case.
2. What is quietly working
The unglamorous truth is that the most reliable win in APAC commercial operations is basic CRM adoption discipline — territories that enforced consistent call logging and account planning in Veeva or Salesforce report cleaner pipeline visibility than any AI layer could produce on its own. Good data hygiene, it turns out, still beats a clever model.
Regional distributor and third-party logistics integration into SAP Business Network has also matured well in markets like Singapore and Australia, where multinationals rely on third-party distributors for the last mile. Track-and-trace compliance, once a scramble ahead of regulatory deadlines, is now largely automated in the markets that mandate it.
3. The gap nobody wants to name in the town hall
Every commercial ops lead in the region names the same frustration once the recorder is off: medical affairs and commercial systems do not talk to each other, and nobody has been willing to force the integration. A rep in Vault CRM cannot easily see that a medical science liaison already answered a doctor’s question last week, so the same HCP gets contacted twice by two different functions asking the same thing in different words. It is not a technology problem so much as a governance one — nobody at regional HQ owns the seam between commercial and medical.
A second pain point is language and market fragmentation. A single global content approval workflow built for English-language, US-style promotional review does not translate cleanly into Japan’s or Korea’s regulatory review cycles, so APAC teams frequently maintain shadow processes just to get materials out the door on time.
4. Where AI is real leverage, and where it is theatre
The real leverage shows up in the boring places: drafting call reports, summarising medical literature for internal briefing packs, and translating approved content across APAC languages while preserving the original claims. Regional teams piloting Microsoft Copilot and ChatGPT Enterprise for these narrow, low-risk tasks report genuine hours saved per rep per week — not transformational, but real.
The theatre shows up whenever a vendor demo promises a fully autonomous “AI agent” managing an entire HCP relationship end to end, with no clear answer for who signs off on what the agent says. In a region with as much regulatory variance as APAC, autonomy without a human checkpoint is not innovation, it is a liability waiting for an inspection.
5. The HQ decisions APAC wishes it had a vote on
The recurring theme is that global platform decisions get made for global reasons — contract economics, data residency in the US or EU, negotiating leverage with a single vendor — and APAC ends up implementing a design built for a different regulatory and language reality. Several regional leads say they wish HQ had consulted them before locking in single-vendor AI assistants that assume English-first workflows, when Japanese, Korean, and Bahasa content review realistically needs its own path.
There is also a quieter frustration about pace: by the time a global AI tool clears legal, security, and procurement review at headquarters, APAC teams have often already found and quietly adopted a faster alternative, creating exactly the shadow IT problem the governance process was meant to prevent.
6. What is actually being piloted in the region
Microsoft Copilot has the widest quiet adoption across APAC affiliates, largely because it rides in on an existing Microsoft 365 licence and does not require a separate procurement battle. ChatGPT Enterprise shows up in medical writing, market research synthesis, and competitive intelligence teams that need faster first drafts. Anthropic’s Claude has smaller but growing usage among data and analytics teams for its handling of long documents and structured reasoning.
Writer is gaining traction specifically for regulated content drafting, since its pitch of built-in brand and compliance guardrails resonates with legal and medical review teams. Palantir AIP and OpenText Aviator appear mostly at the largest multinationals with existing enterprise contracts, more often in supply chain and data governance than in front-line commercial use. Several affiliates, particularly in Singapore and Australia, are also experimenting with in-house builds on top of Azure OpenAI or AWS Bedrock, judging the vendor tools too generic for APAC-specific regulatory language.
The takeaway, if there is one
The technology story in APAC biopharma is not one of falling behind global HQ — it is one of quietly adapting global mandates to fit a region that regulators, languages, and market structures never designed those mandates for in the first place. The systems that work best are not always the newest ones; they are the ones a regional team was actually allowed to shape. Which, if you think about it, is something the next global tooling decision might want to know.
DR. AIDEA - Ideas In Life & healthcare 